Yıl: 2022 Cilt: 31 Sayı: 2 Sayfa Aralığı: 114 - 122 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2022.73636 İndeks Tarihi: 20-07-2022

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Öz:
Objectives: To analyze the change in circulating angiogenic factor levels after transarterial radioembolization (TARE) for colorectal cancer liver metastases (CRCLMs) and its prognostic significance. Methods: Blood samples immediately before TARE and on 1 day, 1 week and 6 weeks after were collected for angiogenic factor analysis in 23 patients. Results: Patients with elevated serum basic fibroblast growth factor and platelet-derived growth factor levels in the 1st week and vascular endothelial growth factor (VEGF) levels in the 6th week after TARE had significantly shorter median overall survival (OS) times. Conclusion: Some early increases in serum angiogenic factor levels and in serum VEGF in the 6th week after TARE for CRCLMs are related to short OS and progression-free survival
Anahtar Kelime:

Yüksek Anjiyojenik Faktör Seviyeleri Kolorektal Kanser Karaciğer Metastazları İçin Transarteriyel Radyoembolizasyon Sonrası Kötü Prognozu Öngörebilir

Öz:
Amaç: Kolorektal kanser metastazları için transarteriyel radyoembolizasyon (TARE) sonrası dolaşımda anjiyojenik faktörlerin seviyelerindeki değişikliklerin analiz edilmesidir. Yöntem: Anjiyojenik faktör analizi için 23 hastada TARE’den hemen önce, 1. günde, 1. haftada ve 6 hafta sonra kan örnekleri toplandı. Bulgular: TARE sonrası 1. haftada bazik fibroblast büyüme faktörü ve platelet kaynaklı büyüme faktörü seviyelerinde ve 6. haftada vasküler endotelyal büyüme faktörü (VEGF) seviyelerinde artış olan hastalarda medyan genel sağkalım süreleri istatistiksel olarak daha kısaydı. Sonuç: Bazı anjiyojenik faktör seviyelerinde erken yükselişler ve kolorektal kanser metastazları için TARE sonrası 6. haftada serum VEGF seviyelerinde artış olması kısa genel sağkalım ve progresyonsuz sağkalım ile ilişkilidir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
  • 2. Silberhumer GR, Paty PB, Temple LK, Araujo RL, Denton B, Gonen M, Nash GM, Allen PJ, DeMatteo RP, Guillem J, Weiser MR, D’Angelica MI, Jarnagin WR, Wong DW, Fong Y. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. Am J Surg 2015;209:935-942.
  • 3. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386-1422.
  • 4. Tsitskari M, Filippiadis D, Kostantos C, Palialexis K, Zavridis P, Kelekis N, Brountzos E. The role of interventional oncology in the treatment of colorectal cancer liver metastases. Ann Gastroenterol 2019;32:147-155. 5. Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med 2017;58(Suppl 2):104S-111S.
  • 6. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711-1720.
  • 7. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28:3687-3694.
  • 8. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/ leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85.
  • 9. Carpizo DR, Gensure RH, Yu X, Gendel VM, Greene SJ, Moore DF, Jabbour SK, Nosher JL. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vasc Interv Radiol 2014;25:297-306.e1.
  • 10. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-3378.
  • 11. Korse CM, Bonfrer JM, Prevoo W, Baas P, Taal BG. Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumour Biol 2011;32:647-652.
  • 12. Lewandowski RJ, Andreoli JM, Hickey R, Kallini JR, Gabr A, Baker T, Kircher S, Salem R, Kulik L. Angiogenic response following radioembolization: results from a randomized pilot study of Yttrium-90 with or without sorafenib. J Vasc Interv Radiol 2016;27:1329-1336.
  • 13. Rosenbaum CE, van den Hoven AF, Braat MN, Koopman M, Lam MG, Zonnenberg BA, Verkooijen HM, van den Bosch MA. Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response. EJNMMI Res 2016;6:92.
  • 14. Alsultan AA, Barentsz MW, Smits MLJ, Koopman M, Lam MGEH, Rosenbaum CENM. Angiogenesis in 90Y-radioembolization of colorectal liver metastases. Semin Nucl Med 2019;49:204-210.
  • 15. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914- 921.
  • 16. Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI, Kim HB, Lee WJ, Kim CM. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037-2044.
  • 17. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004;10:2878-2882.
  • 18. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol 1999;14:1087- 1090.
  • 19. Rahbari NN, Reissfelder C, Mühlbayer M, Weidmann K, Kahlert C, Büchler MW, Weitz J, Koch M. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 2011;18:2182-2191.
  • 20. van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodríguez J, Kröning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1723-1731.
  • 21. Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017;18:1159-1171.
APA SOYDAL Ç, ARAZ M, DURMAZ M, ÖZKAN E, ERGÜDER B, KÜÇÜK N, bilgic s, ELHAN A, GEÇİM İ (2022). Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. , 114 - 122. 10.4274/mirt.galenos.2022.73636
Chicago SOYDAL Çiğdem,ARAZ Mine,DURMAZ Mustafa,ÖZKAN Elgin,ERGÜDER Berrin İmge,KÜÇÜK Nuriye Özlem,bilgic sadık,ELHAN Atilla Halil,GEÇİM İbrahim Ethem Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. (2022): 114 - 122. 10.4274/mirt.galenos.2022.73636
MLA SOYDAL Çiğdem,ARAZ Mine,DURMAZ Mustafa,ÖZKAN Elgin,ERGÜDER Berrin İmge,KÜÇÜK Nuriye Özlem,bilgic sadık,ELHAN Atilla Halil,GEÇİM İbrahim Ethem Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. , 2022, ss.114 - 122. 10.4274/mirt.galenos.2022.73636
AMA SOYDAL Ç,ARAZ M,DURMAZ M,ÖZKAN E,ERGÜDER B,KÜÇÜK N,bilgic s,ELHAN A,GEÇİM İ Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. . 2022; 114 - 122. 10.4274/mirt.galenos.2022.73636
Vancouver SOYDAL Ç,ARAZ M,DURMAZ M,ÖZKAN E,ERGÜDER B,KÜÇÜK N,bilgic s,ELHAN A,GEÇİM İ Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. . 2022; 114 - 122. 10.4274/mirt.galenos.2022.73636
IEEE SOYDAL Ç,ARAZ M,DURMAZ M,ÖZKAN E,ERGÜDER B,KÜÇÜK N,bilgic s,ELHAN A,GEÇİM İ "Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis." , ss.114 - 122, 2022. 10.4274/mirt.galenos.2022.73636
ISNAD SOYDAL, Çiğdem vd. "Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis". (2022), 114-122. https://doi.org/10.4274/mirt.galenos.2022.73636
APA SOYDAL Ç, ARAZ M, DURMAZ M, ÖZKAN E, ERGÜDER B, KÜÇÜK N, bilgic s, ELHAN A, GEÇİM İ (2022). Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. Molecular Imaging and Radionuclide Therapy, 31(2), 114 - 122. 10.4274/mirt.galenos.2022.73636
Chicago SOYDAL Çiğdem,ARAZ Mine,DURMAZ Mustafa,ÖZKAN Elgin,ERGÜDER Berrin İmge,KÜÇÜK Nuriye Özlem,bilgic sadık,ELHAN Atilla Halil,GEÇİM İbrahim Ethem Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. Molecular Imaging and Radionuclide Therapy 31, no.2 (2022): 114 - 122. 10.4274/mirt.galenos.2022.73636
MLA SOYDAL Çiğdem,ARAZ Mine,DURMAZ Mustafa,ÖZKAN Elgin,ERGÜDER Berrin İmge,KÜÇÜK Nuriye Özlem,bilgic sadık,ELHAN Atilla Halil,GEÇİM İbrahim Ethem Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. Molecular Imaging and Radionuclide Therapy, vol.31, no.2, 2022, ss.114 - 122. 10.4274/mirt.galenos.2022.73636
AMA SOYDAL Ç,ARAZ M,DURMAZ M,ÖZKAN E,ERGÜDER B,KÜÇÜK N,bilgic s,ELHAN A,GEÇİM İ Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. Molecular Imaging and Radionuclide Therapy. 2022; 31(2): 114 - 122. 10.4274/mirt.galenos.2022.73636
Vancouver SOYDAL Ç,ARAZ M,DURMAZ M,ÖZKAN E,ERGÜDER B,KÜÇÜK N,bilgic s,ELHAN A,GEÇİM İ Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis. Molecular Imaging and Radionuclide Therapy. 2022; 31(2): 114 - 122. 10.4274/mirt.galenos.2022.73636
IEEE SOYDAL Ç,ARAZ M,DURMAZ M,ÖZKAN E,ERGÜDER B,KÜÇÜK N,bilgic s,ELHAN A,GEÇİM İ "Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis." Molecular Imaging and Radionuclide Therapy, 31, ss.114 - 122, 2022. 10.4274/mirt.galenos.2022.73636
ISNAD SOYDAL, Çiğdem vd. "Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis". Molecular Imaging and Radionuclide Therapy 31/2 (2022), 114-122. https://doi.org/10.4274/mirt.galenos.2022.73636